Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24403220 | 0.88 | MME (0.41) | GAAF10F2PRSS1CTSK | |
| SCHEMBL5936027 | 0.88 | GAA (0.39) | GAAF10F2PRSS1CTSK | |
| SCHEMBL13928417 | 0.88 | MME (0.41) | GAAF10F2PRSS1CTSK | |
| SCHEMBL3470249 | 0.88 | MME (0.41) | GAAF10F2PRSS1CTSK | |
| SCHEMBL4704301 | 0.88 | GAA (0.39) | GAAF10F2PRSS1CTSK | |
| SCHEMBL22636099 | 0.85 | KMT2A (0.38) | GAAF10F2PRSS1CTSK | |
| SCHEMBL22636100 | 0.85 | KMT2A (0.38) | GAAF10F2PRSS1CTSK | |
| SCHEMBL6800613 | 0.84 | GAA (0.43) | GAAF10F2PRSS1CTSK | |
| SCHEMBL6800616 | 0.84 | GAA (0.43) | GAAF10F2PRSS1CTSK | |
| SCHEMBL6802644 | 0.84 | GAA (0.43) | GAAF10F2PRSS1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1076645-B1 | PROCESS FOR THE PREPARATION OF METHYL(2S)-2-[(3R)-3-(N-[TERT-BUTYLOXYCARBONYL]-AMINO) -2-OXOPYRR OLIDIN-1-YL]PROPIONATE | ASTRAZENECA AB (SE) | 2004-03-03 | — | — | EP | disclosed |
| US-20020187934-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2002-12-12 | — | — | US | disclosed |
| EP-1076645-A1 | PROCESS FOR THE PREPARATION OF METHYL(2S)-2-[(3R)-3-(N-[TERT-BUTYLOXYCARBONYL]-AMINO) -2-OXOPYRR OLIDIN-1-YL]PROPIONATE | AstraZeneca AB (SE) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055669-A1 | PROCESS FOR THE PREPARATION OF METHYL(2S)-2-[(3R)-3-(N-[TERT-BUTYLOXYCARBONYL]-AMINO)-2-OXOPYRROLIDIN-1-YL]PROPIONATE | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187934-A1 | Peptide derivatives | HLA-DRB1, MICA, TAP1 | GAA 4428/4885F10 1531/4885F2 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.